The FDA's written responses aligned with the company's proposals in a way that the End-of-Phase 2 meeting was deemed unnecessary. We ready a robust and innovative scientific trial plan and so are happy with the FDA's positive feedback that enables us to move straight into the ALKS 5461 phase 3 system in early 2014, said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. There exists a apparent and compelling dependence on a novel system for the treating unhappiness, and ALKS 5461 displays a new approach predicated on modulation of the opioid program in the mind. .. Alkermes announces programs to advance ALKS 5461 phase 3 system for major depressive disorder Alkermes plc today announced that it offers successfully completed its End-of-Stage 2 interactions with the U.S.This article is normally republished with kind authorization from our friends at The Kaiser Family Foundation. You will see the complete Kaiser Daily Health Plan Record, search the archives, or join email delivery of in-depth coverage of health policy developments, discussions and debates. The Kaiser Daily Wellness Policy Report is released for Kaisernetwork.org, a free support of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Kaiser and Company Family members Foundation. All rights reserved.S. Food and Drug Administration .